Patents by Inventor Thomas A. Reh
Thomas A. Reh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220193265Abstract: Nucleic acid molecules and compositions, and methods using the same are provided herein for intraocular gene-based delivery and expression of two or more proneural bHLH transcription factors in the retina. The nucleic acid molecules, compositions and methods disclosed herein stimulate regeneration of retinal interneurons from retinal Müller glia (MG) and reprogram the MG into bipolar, amacrine, horizontal, and/or ganglion cells. Such methods and nucleic acid molecules are used for vision restoration and/or treatment of a range of ocular diseases involving retinal degeneration after injury, disease, or vison loss.Type: ApplicationFiled: April 29, 2020Publication date: June 23, 2022Applicant: UNIVERSITY OF WASHINGTONInventors: Thomas A. REH, Nikolas L. JORSTAD, Levi TODD
-
Publication number: 20210228741Abstract: Methods and compositions are provided for regeneration of retinal neurons and vision restoration after injury, disease, or loss comprising, administration of a nucleic acid sequence encoding Ascl1 and retinal reprogramming potentiating agents, including HDAC inhibitors, STAT-signaling inhibitors and microRNA manipulations in Ascl1-induced retinal regeneration.Type: ApplicationFiled: April 29, 2019Publication date: July 29, 2021Applicant: UNIVERSITY OF WASHINGTONInventors: Thomas A. REH, Nikolas L. JORSTAD, Stefanie G. WOHL
-
Patent number: 10849904Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.Type: GrantFiled: June 20, 2019Date of Patent: December 1, 2020Assignees: University of Washington, The J. David Gladstone Institutes, a Teatamentary Trust Established Under the Will of J. David. GladstoneInventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
-
Publication number: 20200368234Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject using Photoregulin3 (PR3).Type: ApplicationFiled: August 10, 2018Publication date: November 26, 2020Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J David GladstInventors: Thomas A. Reh, Paul Nakamura, Andy Shimchuk, Shibing Tang, Sheng Ding
-
Publication number: 20190381047Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.Type: ApplicationFiled: June 20, 2019Publication date: December 19, 2019Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David GladsInventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
-
Patent number: 10363256Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.Type: GrantFiled: March 28, 2016Date of Patent: July 30, 2019Assignees: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David GladstoneInventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
-
Publication number: 20180125847Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.Type: ApplicationFiled: March 28, 2016Publication date: May 10, 2018Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David GladsInventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
-
Patent number: 8557972Abstract: The present invention provides reagents and methods for RNA transfection and protein expression.Type: GrantFiled: December 21, 2010Date of Patent: October 15, 2013Assignee: University of Washington through its Center for CommercializationInventors: Thomas A. Reh, Olivia M. Bermingham-McDonogh, Toshinori Hayashi
-
Publication number: 20110151557Abstract: The present invention provides reagents and methods for RNA transfection and protein expressionType: ApplicationFiled: December 21, 2010Publication date: June 23, 2011Applicant: University of WashingtonInventors: Thomas A. Reh, Olivia M. Bermingham-McDonogh, Toshinori Hayashi
-
Publication number: 20110044957Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.Type: ApplicationFiled: August 23, 2010Publication date: February 24, 2011Applicant: University of WashingtonInventors: Ryo KUBOTA, Thomas A. Reh, Andrew J. Fischer
-
Publication number: 20110004272Abstract: In one aspect, the invention provides vision prosthesis systems. Exemplary vision prosthesis systems of the invention comprise a light energy generator operably connected to a wearable head piece comprising a device for directing light energy produced by the light energy generator onto a mammalian retina, wherein the light energy generator is tuned to emit light energy of sufficient power to modulate neural activity in the retina. In another aspect, the invention provides methods for irradiating neurons in the retina of the mammalian eye by directing light energy produced by a light energy generator onto a mammalian retina. The methods of the invention may be used to directly modulate the activity of retinal neurons or to introduce molecules into retinal cells.Type: ApplicationFiled: November 8, 2007Publication date: January 6, 2011Applicant: WASHINGTON, UNIVERSITY OFInventors: Eric J. Seibel, Thomas A. Reh, Blake Miller
-
Publication number: 20080175826Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.Type: ApplicationFiled: November 16, 2007Publication date: July 24, 2008Applicant: University of WashingtonInventors: Ryo Kubota, Thomas A. Reh, Andrew J. Fischer
-
Patent number: 7311723Abstract: In one aspect, the invention provides vision prosthesis systems. Exemplary vision prosthesis systems of the invention comprise a light energy generator operably connected to a wearable head piece comprising a device for directing light energy produced by the light energy generator onto a mammalian retina, wherein the light energy generator is tuned to emit light energy of sufficient power to modulate neural activity in the retina. In another aspect, the invention provides methods for irradiating neurons in the retina of the mammalian eye by directing light energy produced by a light energy generator onto a mammalian retina. The methods of the invention may be used to directly modulate the activity of retinal neurons or to introduce molecules into retinal cells.Type: GrantFiled: July 9, 2004Date of Patent: December 25, 2007Assignee: University of WashingtonInventors: Eric J. Seibel, Thomas A. Reh, Blake Miller
-
Patent number: 7312025Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.Type: GrantFiled: July 11, 2003Date of Patent: December 25, 2007Assignee: University of WashingtonInventors: Ryo Kubota, Thomas A Reh, Andrew J Fischer
-
Publication number: 20040147019Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.Type: ApplicationFiled: July 11, 2003Publication date: July 29, 2004Applicant: University of WashingtonInventors: Ryo Kubota, Thomas A. Reh, Andrew J. Fischer
-
Patent number: 6750196Abstract: In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to provide these effects may be achieved by contacting retinal cells with a polypeptide described herein. The treatments may be provided to slow or halt net cell loss or to increase the amount or quality of retinal tissue present in the vertebrate.Type: GrantFiled: March 27, 1995Date of Patent: June 15, 2004Assignee: Acorda TherapeuticsInventors: Thomas A. Reh, Mark A. Marchionni, Kathryn L. McCabe, Olivia Bermingham-McDonogh, Nagesh K. Mahanthappa, David I. Gwynne